Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines.

[1]  Z. Jóźwiak,et al.  Involvement of reactive oxygen species in aclarubicin-induced death of human trisomic and diabetic fibroblasts. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[2]  C. Addison,et al.  Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. , 2007, Cancer letters.

[3]  P. Conte,et al.  Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives. , 2007, Cancer letters.

[4]  L. Goya,et al.  Quercetin protects human hepatoma HepG2 against oxidative stress induced by tert-butyl hydroperoxide. , 2006, Toxicology and applied pharmacology.

[5]  Shenglin Ma,et al.  A combined treatment TNF-alpha/doxorubicin alleviates the resistance of MCF-7/Adr cells to cytotoxic treatment. , 2006, Biochimica et biophysica acta.

[6]  A. Koceva-Chyła,et al.  Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: Relation to drug cytotoxicity and caspase-3 activation , 2005, Apoptosis.

[7]  S. Mateos,et al.  Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. , 2005, Mutation research.

[8]  Y. Hiraku,et al.  Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. , 2005, Life sciences.

[9]  A. Samsudin,et al.  The Effects of Chemotherapeutic Drugs on Viabilty, Apoptosis, and Survivin Expression in MCF-7 Cells , 2005 .

[10]  D. Ravi,et al.  Redox-cycling of anthracyclines by thioredoxin system: increased superoxide generation and DNA damage , 2004, Cancer Chemotherapy and Pharmacology.

[11]  Joy Joseph,et al.  Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms , 2004, Journal of Biological Chemistry.

[12]  M. Polette,et al.  Assessment of the antiinvasive potential of the anthracycline aclacinomycin (Aclarubicin) in a human fibrosarcoma cell line. , 2004, International journal of oncology.

[13]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[14]  W. Kolch,et al.  Comparison of anthracycline-induced death of human leukemia cells: Programmed cell death versus necrosis , 2002, Apoptosis.

[15]  S. Kong,et al.  Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. , 2003, Life sciences.

[16]  K. Wallace,et al.  Doxorubicin-induced cardiac mitochondrionopathy. , 2003, Pharmacology & toxicology.

[17]  R. Duval,et al.  Sensitive and reliable JC‐1 and TOTO‐3 double staining to assess mitochondrial transmembrane potential and plasma membrane integrity: Interest for cell death investigations , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[18]  C. Leeuwenburgh,et al.  Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. , 2002, Biochimica et biophysica acta.

[19]  B. Chénais,et al.  Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines. , 2002, Leukemia research.

[20]  B. van de Water,et al.  Differential Regulation of Doxorubicin-induced Mitochondrial Dysfunction and Apoptosis by Bcl-2 in Mammary Adenocarcinoma (MTLn3) Cells* , 2002, The Journal of Biological Chemistry.

[21]  G. Kroemer,et al.  Mitochondria, the killer organelles and their weapons , 2002, Journal of cellular physiology.

[22]  B. Chénais,et al.  Involvement of reactive oxygen species in aclarubicin-induced differentiation and invasiveness of HL-60 leukemia cells. , 2002, International journal of oncology.

[23]  Li Jia,et al.  Liposomal encapsulation diminishes daunorubicin‐induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukaemic cells , 2002, British journal of haematology.

[24]  A. Matouschek,et al.  Protein unfolding by the mitochondrial membrane potential , 2002, Nature Structural Biology.

[25]  R. Reszka,et al.  Mitochondria as subcellular targets for clinically useful anthracyclines. , 2001, Advanced drug delivery reviews.

[26]  P. Burke,et al.  Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin. , 2001, Anticancer research.

[27]  S. Dan,et al.  Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells. , 2001, Biochemical and biophysical research communications.

[28]  A. Kulma,et al.  A comparison of the methods applied to detect apoptosis in genotoxically-damaged lymphocytes cultured in the presence of four antimutagens. , 2001, Cellular & molecular biology letters.

[29]  John Calvin Reed,et al.  Mitochondria-dependent apoptosis and cellular pH regulation , 2000, Cell Death and Differentiation.

[30]  P. Guiraud,et al.  Oxidative stress involvement in chemically induced differentiation of K562 cells. , 2000, Free radical biology & medicine.

[31]  H. Geerts,et al.  A rapid method for the evaluation of compounds with mitochondria-protective properties , 1999, Journal of Neuroscience Methods.

[32]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[33]  S. Oikawa,et al.  Generation of hydrogen peroxide precedes loss of mitochondrial membrane potential during DNA alkylation‐induced apoptosis , 1999, FEBS letters.

[34]  G. Kroemer,et al.  Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. , 1998, Immunology letters.

[35]  Y. Pommier,et al.  Aclacinomycin A stabilizes topoisomerase I covalent complexes. , 1997, Cancer research.

[36]  A. Bast,et al.  Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. , 1996, European journal of cancer.

[37]  G. Kroemer,et al.  Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death , 1995, The Journal of experimental medicine.

[38]  H. Marquardt,et al.  DMSO-like rapid decrease in c-myc and c-myb mRNA levels and induction of differentiation in HL-60 cells by the anthracycline antitumor antibiotic aclarubicin. , 1995, Leukemia.

[39]  C. Schmidt,et al.  Induction of differentiation in Friend-erythroleukemia cells by aclacinomycin A: early transient decrease in c-myc and c-myb mRNA levels. , 1992, Leukemia.

[40]  G. Steele,et al.  Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Waring,et al.  Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. , 1990, Biochemistry.

[42]  G. Schuurhuis,et al.  Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. , 1990, Pharmacology & therapeutics.

[43]  G. Batist,et al.  Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. , 1987, Biochemistry.

[44]  J. Minna,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. , 1987, Cancer research.

[45]  J. Doroshow,et al.  Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. , 1986, The Journal of biological chemistry.

[46]  J. Doroshow,et al.  Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. , 1986, The Journal of biological chemistry.